Drugs / 18F-fludeoxyglucose
18F-fludeoxyglucose
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01806675 | Mar 2013 → Dec 2016 | adenoid cystic carcinoma, adult glioblastoma, cancer of unknown primary site, carcinoma of lip +22 | Sanjiv Sam Gambhir | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03231397 | Aug 2017 → Apr 2020 | abdominal aortic aneurysm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-fludeoxyglucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01806675 ↗ |
| Known as | 18F-FDG | “Drug: 18F-fludeoxyglucose (18F-FDG)” NCT01806675 ↗ |
| Known as | FDG | “The radioactive tracers that are used in this study are 18F-fludeoxyglucose (FDG) and 11C-PBR28 (PBR) which stands for Peripheral Benzodiazepine Receptor.” NCT03231397 ↗ |
| Modality | Diagnostic / imaging agent | “18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan” NCT01806675 ↗ |